Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRDye800CW-BBN PET-NIRF in Lower Grade Glioma
NCT03407781Phase 1Completed
- Start
- Jan 2016
- Primary completion
- Aug 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-BBN-IRDye800CW in glioma. Primary endpoint: Standardized uptake value of 68Ga-BBN-IRDye800CW at 1 year. Started Jan 2016; status: completed.
02
Drugs
68Ga-BBN-IRDye800CW
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03407781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407781.